It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. So, the shares are expected to perform in line with the market in the near future. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Īhead of this earnings release, the estimate revisions trend for SurModics: mixed.
Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Įmpirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. While SurModics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? SurModics shares have lost about 16.1% since the beginning of the year versus the S&P 500's decline of -12.4%. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. The company has topped consensus revenue estimates two times over the last four quarters. This compares to year-ago revenues of $35 million. SurModics, which belongs to the Zacks Medical - Products industry, posted revenues of $26.11 million for the quarter ended March 2022, surpassing the Zacks Consensus Estimate by 6.99%.
0 kommentar(er)
